Key result
B-CAT score best predicts 6-month bleeding in cancer-associated thrombosis while DASH modestly predicts VTE recurrence.
Why the study?
Do existing risk scores accurately predict bleeding and recurrent VTE in patients with cancer-associated thrombosis on anticoagulant therapy?
Do existing risk scores accurately predict bleeding and recurrent VTE in patients with cancer-associated thrombosis on anticoagulant therapy?
The B-CAT score is a valid tool for predicting 6-month bleeding risk in patients with cancer-associated thrombosis, whereas existing scores for VTE recurrence perform poorly.
Answers are grounded in this paper and cite their sources.
B-CAT may aid bleeding risk assessment in cancer-associated thrombosis; leaves open need for improved VTE recurrence predictors.
BACKGROUND Cancer-associated thrombosis (CAT) requires balancing recurrent venous thromboembolism (VTE) risk against bleeding from anticoagulation. Most risk scores are not specific for CAT, limiting their accuracy, while cancer-specific tools lack robust external validation. OBJECTIVES This study aimed to externally validate risk scores for predicting bleeding and recurrent VTE within 6 months in patients with CAT receiving anticoagulants. PATIENTS/METHODS We conducted a retrospective cohort study of 1203 patients with CAT from a hospital registry between 2007 and 2022. Primary outcomes were clinically relevant bleeding (CRB) and recurrent VTE within 6 months. Ten bleeding (B-CAT, CAT-BLEED, ACCP-VTE, HAS-BLED, HEMORR2HAGES, VTE-BLEED, Kuijer, Martinez, Nieto and RIETE) and four recurrence scores (Ottawa, RIETE, HERDOO2, DASH) were assessed. Predictive performance was evaluated using the area under the receiver operating characteristic curve (AUC) for discrimination. For risk stratification analyses, odds ratios (OR) were calculated to assess the association between risk categories and primary outcomes. RESULTS Among 1203 patients (mean age 63.9 ± 12.7 years; 52.6% male), 65 experienced CRB (5.4%) and 60 developed recurrent VTE (5.0%) within 6 months. Of the bleeding models, only the original three-category B-CAT score showed acceptable discriminative performance (c-statistic 0.70; 95% CI: 0.64-0.75), stratifying patients into low-, intermediate-, and high-risk groups with CRB incidences of 1.6%, 5.8%, and 20.4% (p < 0.001). For recurrent VTE, only the modified DASH score showed modest predictive ability (c-statistic 0.58; 95% CI: 0.52-0.64; p = 0.01), with recurrent VTE rates of 3.3% in the low-risk group and 6.3% in the high-risk group. CONCLUSIONS In this real-world CAT cohort, the B-CAT score was externally validated as the best predictor of 6-month bleeding risk, while the modified DASH score showed only modest predictive ability for VTE recurrence.
No takes yet. Share an insight, caveat, or question.
Barca-Hernando et al. (2026) studied this question. The B-CAT score best predicted 6-month bleeding risk in cancer-associated thrombosis, while the modified DASH score modestly predicted VTE recurrence.
Synapse has enriched 10 related papers. Consider them for comparative context: